Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Victoria Lock"'
Autor:
Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Supplementary Figure 1. Examples of changes observed in M30/M65 profiles as a function of dosing of AT9283 in two selected patients. Pt. 58/032 from cohort 4 (14.5 mg/m2/day) and Pt. 31/030 from cohort 6 (23 mg/m2/day).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecad42031facf935942fc7b688af840e
https://doi.org/10.1158/1078-0432.22460577.v1
https://doi.org/10.1158/1078-0432.22460577.v1
Autor:
Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Supplementary Table 1. Summary of pharmacodynamic changes observed in paired skin punch biopsies. Skin punch biopsies were optional until a dose limiting toxicity was found (11.5 mg/m2/day) when they were mandated. Inhibition of pHH3 (substrate for A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::950e620f9c4ac0b51c81c065ed2a89b6
https://doi.org/10.1158/1078-0432.22460574
https://doi.org/10.1158/1078-0432.22460574
Autor:
Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Purpose: A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify maximum-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ebdd8f39fe18202f828f43bd11730ed
https://doi.org/10.1158/1078-0432.c.6524535.v1
https://doi.org/10.1158/1078-0432.c.6524535.v1
Autor:
Christopher William Murray, Joseph E. Coyle, Sharna J. Rich, Anne Cleasby, Tracey Ann Sambrook, S. Saalau-Bethell, Jeff Yon, Valerio Berdini, Mladen Vinkovic, Victoria Lock, M. Alistair O’Brien, Miles Congreve, Harren Jhoti
Publikováno v:
'ChemMedChem ', vol: 9, pages: 823-832 (2014)
Chemmedchem
Chemmedchem
Soluble adenylate cyclases catalyse the synthesis of the second messenger cAMP through the cyclisation of ATP and are the only known enzymes to be directly activated by bicarbonate. Here, we report the first crystal structure of the human enzyme that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c763854d609cb5fa0221a0ecc011d10d
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:39648
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:39648
Autor:
Tomislav Dragovich, H. Calvert, M. Squires, C. Pretzinger, D. M. Rensvold, Sandy Kurtin, Daruka Mahadevan, Victoria Lock, Ruth Plummer, Donna M. Smith, D. D. Von Hoff, J. Adams
Publikováno v:
Annals of Oncology. 22:2137-2143
Background AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs). Based on potent antitumor activity in preclinical models, a first-in-human clinical trial in refractory solid tumors investigated its safety, tolerability, pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b84104ee8f260b2f7449680584ecc3ed
https://doi.org/10.1093/annonc/mdq734
https://doi.org/10.1093/annonc/mdq734
Autor:
Murray Yule, Andrew D.J. Pearson, Victoria Lock, Guy Makin, Martin Elliott, Quentin Campbell-Hewson, Gary Acton, MJ Griffin, Lynley V. Marshall, Philip Ross, Ana Rodriguez, Bruce Morland, Sarah Halford, John Lyons, Lucas Moreno, Darren Hargrave, Shamim Kazmi-Stokes, Alan V. Boddy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(2)
Purpose: A phase I trial of AT9283 (a multitargeted inhibitor of Aurora kinases A and B) was conducted in children and adolescents with solid tumors, to identify maximum-tolerated dose (MTD), safety, efficacy, pharmacokinetics, and pharmacodynamic (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::954a4d387e5c5749bf997611a7d2e6de
https://pubmed.ncbi.nlm.nih.gov/25370467
https://pubmed.ncbi.nlm.nih.gov/25370467
Autor:
Srdan Verstovsek, Tapan M. Kadia, Farhad Ravandi, William G. Wierda, James M. Foran, John Lyons, Gillian Langford, Guillermo Garcia-Manero, Jan A. Burger, Victoria Lock, Murray Yule, John Ayrton, Hagop M. Kantarjian, Jorge E. Cortes, Gautham Borthakur
Background This study sought to identify the maximum tolerated dose (MTD) of AT9283, an inhibitor of Aurora kinases A and B, in patients with relapsed or refractory leukemias. Other endpoints included pharmacokinetics, safety and tolerability, pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::102f51373f49c01bac1873ad68c74af2
https://europepmc.org/articles/PMC4096861/
https://europepmc.org/articles/PMC4096861/
Autor:
John Lyons, Murray Yule, David Olmos, T. A. Yap, M. Squires, H. Calvert, H.-T. Arkenau, Ian Judson, L. R. Molife, Ruth Plummer, S. Lewis, Victoria Lock
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 23(5)
BACKGROUND: AT9283 is an inhibitor of aurora kinases A and B with antitumor activity in preclinical models. This a First in Human phase I study assessed the safety, tolerability, pharmacokinetic and pharmacodynamic properties and preliminary efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad453018db633cda3506b896158d571f
https://pubmed.ncbi.nlm.nih.gov/22015452
https://pubmed.ncbi.nlm.nih.gov/22015452
Autor:
T.G. Davies, Lisa Jane K. Hunter, Michelle D. Garrett, Matthias Reule, Timothy A. Yap, Lisa C A Seavers, Steven John Woodhead, Kyla Grimshaw, Lynsey Fazal, Neil T. Thompson, John Lyons, Paul Workman, Simon P. Heaton, Michael I. Walton, Victoria Lock
Publikováno v:
Molecular cancer therapeutics. 9(5)
The serine/threonine kinase AKT plays a pivotal role in signal transduction events involved in malignant transformation and chemoresistance and is an attractive target for the development of cancer therapeutics. Fragment-based lead discovery, combine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18db0a9162a3f0e3bc7cd70c795c6c6
https://pubmed.ncbi.nlm.nih.gov/20423992
https://pubmed.ncbi.nlm.nih.gov/20423992
Autor:
Laurence Cooke, Neil T. Thompson, Victoria Lock, Matthew S Squires, Daruka Mahadevan, E. Jonathan Lewis, Wenqing Qi, John Lyons
Publikováno v:
Molecular cancer therapeutics. 9(4)
AT7519 is a potent inhibitor of several cyclin-dependent kinases and is currently in early phase clinical development. Recently, cyclin-dependent kinases 7, 8, and 9 have been shown to regulate transcription through phosphorylation of RNA polymerase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0287391e30e7837711450ae5f6bf68
https://pubmed.ncbi.nlm.nih.gov/20354122
https://pubmed.ncbi.nlm.nih.gov/20354122